{"id":"W3132138449","doi":"10.33380/2305-2066-2021-10-1-31-36","title":"PD-L1 as a Potential Target in Cancer Therapy (Review)","year":2021,"lang":"en","type":"article","venue":"Drug development & registration","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Durvalumab; Avelumab; Immunotherapy; Immune system; Cancer; Medicine; Clinical trial; Cancer immunotherapy; Mechanism (biology); Immunology; Cancer research; Internal medicine; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003368657,0.0007589184,0.001088703,0.001331264,0.0002501221,0.001147422,0.0007385066,0.0009487696,0.006539631],"category_scores_gemma":[0.0005530548,0.000178044,0.0008002788,0.00130907,0.0002378874,0.0009595878,0.0004645094,0.001716874,0.001764314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006314854,"about_ca_system_score_gemma":0.001208326,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008590839,"about_ca_topic_score_gemma":0.001468478,"domain_scores_codex":[0.9998241,0.00002934021,0.00002512331,0.00003617605,0.00006389731,0.00002140878],"domain_scores_gemma":[0.9997826,0.00007352878,0.0000457966,0.000005459629,0.00007305181,0.00001956455],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001191727,0.00005787882,0.0001189418,0.03370581,0.0001479464,0.0001361413,0.00003626039,0.0004127736,0.001044256,0.001919592,0.07928044,0.8830209],"study_design_scores_gemma":[0.00003711502,0.0001372297,0.0006406329,0.008088239,0.0002688336,0.001046126,0.00003968523,0.000113577,0.000385755,0.001154149,0.9880704,0.00001834824],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001311179,0.9979091,0.0001063846,0.0004335492,0.0005101539,0.00001078594,0.00004959569,0.0000100452,0.0008391099],"genre_scores_gemma":[0.001035508,0.9970207,0.0001627763,0.0004860378,0.0003553001,0.00001565804,0.000097251,0.000001710471,0.0008250638],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006539631,"threshold_uncertainty_score":0.02187729,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01983293940426857,"score_gpt":0.3036877309930628,"score_spread":0.2838547915887942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}